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ABSTRACT
Introduction Using a type 2 hybrid effectiveness- 
implementation design, we aim to pilot a diabetic 
retinopathy (DR) care pathway in the public health system 
in Kerala to understand how it can be scaled up to and 
sustained in the whole state.
Methods and analysis Currently, there is no systematic 
DR screening programme in Kerala. Our intervention is 
a teleophthalmology pathway for people with diabetes 
in the non- communicable disease registers in 16 family 
health centres. The planned implementation strategy of the 
pathway will be developed based on the discrete Expert 
Recommendations for Implementing Change taxonomy. We 
will use both quantitative data from a cross- sectional study 
and qualitative data obtained from structured interviews, 
surveys and group discussions with stakeholders to report 
the effectiveness of the DR care pathway and evaluation of 
the implementation strategy.
We will use logistic regression models to assess 
crude associations DR and sight- threatening diabetic 
retinopathy and fractional polynomials to account for 
the form of continuous covariates to predict uptake of 
DR screening. The primary effectiveness outcome is 
the proportion of patients in the non- communicable 
disease register with diabetes screened for DR over 12 
months. Other outcomes include cost- effectiveness, 
safety, efficiency, patient satisfaction, timeliness and 
equity. The outcomes of evaluation of the implementation 
strategies include acceptability, feasibility, adoption, 
appropriateness, fidelity, penetration, costs and 
sustainability. Addition of more family health centres 
during the staggered initial phase of the programme will 
be considered as a sign of acceptability and feasibility. 
In the long term, the state- wide adoption of the DR care 
pathway will be considered as a successful outcome of 
the Nayanamritham study.
Ethics and dissemination The study was approved by 
Indian Medical Research Council (2018-0551) dated 13 
March 2019. Study findings will be disseminated through 
scientific publications and the report will inform adoption 
of the DR care pathway by Kerala state in future.
Trial registration number ISRCTN28942696.
INTRODUCTION
Background
The triad of diabetes, blindness and poverty is an 
urgent problem that needs an effective response 
in the Development Assistance Committee- 
listed countries as these countries are home to 
80% of people with diabetes.1 Diabetic retinop-
athy (DR) is one of the most common compli-
cations of diabetes.2 Sight- threatening diabetic 
retinopathy (STDR) is a common cause of 
blindness in working- age people and unless this 
condition is managed early, it has considerable 
impact on the quality of life and productivity of 
the person and their family, as well as substan-
tial financial costs to health systems.3 In its early 
stages, STDR may be asymptomatic. Therefore, 
DR screening programmes are essential to iden-
tify STDR to enable timely treatment.4 In DR 
screening programmes in high- income coun-
tries, people with diabetes are systematically 
screened using office- based retinal cameras 
Strength and limitations of this study
 ► This study will examine the clinical and cost effec-
tiveness of a new diabetic retinopathy care pathway 
at the patient, clinician and service levels and eval-
uate the implementation strategy within a resource 
constrained environment.
 ► This type 2 hybrid effectiveness- implementation 
study will use mixed methods as method of 
evaluation.
 ► The specific actions in the implementation strate-
gy are based on the Expert Recommendations for 
Implementing Change taxonomy.
 ► The study outlines the economic evaluation of the 
costs of the diabetic retinopathy care pathway.
 ► The study is limited by the absence of a comparator 
due to lack of previous data on the prevalence of 
diabetic retinopathy in the public health system.
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and the retinal images are graded according to severity of 
DR by dedicated accredited screeners and graders. Patients 
with STDR are identified and referred to ophthalmologists 
for timely treatment with laser and/or intravitreal injec-
tions of antivascular endothelial growth factor.4 In order to 
successfully reduce the risk of blindness due to DR in low- 
middle income countries (LMICs), without a well- developed 
primary care infrastructure, the pathway needs to begin with 
systematically screening for diabetes, educating the public 
and healthcare professionals on early detection5 and timely 
treatment of STDR and the need to optimally treat the risk 
factors for DR such as hyperglycaemia, hypertension and 
hyperlipidaemia.2 Moreover, DR screening and treatment 
are challenging due to the required technology and tech-
nical expertise needed to grade retinal images and deliver 
costly treatment options, adding to the cost and complexity 
of the required interventions.
Diabetes in Kerala
Kerala is the most advanced state in India in terms of literacy, 
health, social uplift and demographic transition.6 This has 
been accompanied by high prevalence of diabetes. A recent 
report from Kerala suggests that one in five of the Kerala 
adult population may have diabetes.7 The Government of 
Kerala launched the Aardram Mission in 2017 to transform 
and gear up the State’s public healthcare system to achieve 
the sustainable development goals (SDGs) in phases with 
short- term goals on building infrastructure and quality care 
services. The overarching objectives of the Aardram Mission 
included providing equitable, affordable and quality care 
to citizens from all socioeconomic strata; strengthening the 
public care system by decentralising healthcare from the 
secondary and tertiary levels to primary care- led services 
and initiating preventive medicine to address the impact of 
non- communicable diseases, especially hypertension and 
diabetes. Primary care centres have been converted to family 
health centres (FHCs) with three doctors and four nurses in 
each FHC assigned to provide individual care plans to the 
allocated population whose records are tracked through a 
recently established electronic health records (EHR) called 
eHealth. The transformation of primary care with a focus on 
non- communicable diseases provided the backdrop to the 
implementation of a DR care pathway.
The rationale for a complex DR care pathway
The Government of Kerala is pressing forward to achieve 
universal health coverage and address the SDG on poverty 
(SDG 1), health access (SDG 3), education (SDG 4) and 
gender equality (SDG 5).8 9 Therefore, there is an urgent 
need to tackle the complications of diabetes. Systematic 
DR screening has been shown to be effective in reducing 
blindness.3 However, in high- income countries, DR 
screening is achieved by dedicated services due to the 
technicalities and expertise required in DR screening and 
evaluation.10–12 Introducing an isolated DR care pathway 
will not be sufficient to address the challenge in LMICs as 
these countries need to initiate holistic screening service 
for diabetes and all its complications simultaneously and 
embed DR screening within the primary care.
Rationale for an implementation strategy
Each aspect of the DR screening and care pathway has to 
be adapted to local needs and resources, requiring a locally 
appropriate implementation strategy. For example, mydri-
asis (pupil dilatation) is compulsory in some screening 
programmes but not in others and this process requires 
local approval by stakeholders.10–12 In Kerala, mydriasis 
needs to be approved by the health department. Other 
issues faced by LMICs are that the number of undiagnosed 
diabetes cases is high,13 the non- availability of a state- wide 
diabetes register with recall facilities, the lack of resources 
for standardised non- portable retinal cameras, limited 
capacity of staff in primary care to screen for DR and that the 
number of people with diabetes is larger than the capacity 
of the services provided by the secondary care hospitals.14–16 
Research capacity and capability are in their infancy in 
LMICs and implementing change in a busy environment 
when demands on staff are great and resources are limited 
is challenging.15 16 In addition, as cataract is more prevalent 
in LMICs,17 the proportion of ungradable retinal images is 
higher compared with developed countries.17–19 Therefore, 
we need to evaluate the implementation strategy using both 
qualitative and quantitative methods.20–22
Aims and objectives
The Nayanamritham study is facilitated by a UK- Government 
of Kerala partnership as a part of the ORNATE- India project 
funded by Global Challenges Research Fund (GCRF) and 
UK Research and Innovation (UKRI). We aim to introduce 
a DR care pathway that spans primary, secondary and tertiary 
care in the public health system in Kerala in a pilot study in 
Thiruvananthapuram. The proposed study will (1) examine 
the clinical and cost effectiveness of the DR care pathway at 
the patient, clinician and service levels and (2) evaluate the 
implementation strategy of the pathway.
METHODS
Design
We chose a type 2 hybrid effectiveness- implementation 
design to evaluate the effectiveness of the clinical inter-
ventions and the implementation strategies.20–23 Mixed 
methods will be used as the method of evaluation. DR care 
pathway was developed by the Kerala Health Secretary, non- 
communicable diseases lead, Health and Medical Education 
service providers, technical and EHR teams, local authorities 
and the GCRF/UKRI- funded coapplicants from the UK. The 
DR care pathway will be set- up in a staggered approach with 
five FHCs initiated in the first 3 months and the remaining 
11 centres will be added based on acceptance of all stake-
holders and adapting and training phase for 12 months 
from 15 March 2018. A further 12–15 months will be allo-
cated to recruit consenting patients to a cross- sectional study 
to gather quantitative data for the effectiveness outcomes. 
A minimal data set from this study will also be entered into 
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EHR to enable future screening for the consented patients. 
Qualitative data collection from interviews of staff, patients 
and focus groups at baseline and end of study and all field 
notes gathered during the study will be utilised to inform 
evaluation of the implementation strategy.20–22
Target population
People with diabetes registered in the non- communicable 
diseases register at 16 FHCs in Thiruvananthapuram 
district will be invited to be screened for complications 
of diabetes including screening for DR. As the non- 
communicable diseases register is likely to show an 
increase in newly diagnosed diabetes as a result of training 
the accredited social health activists (ASHAs), in diabetes 
and DR, we will evaluate the effectiveness of the complex 
interventions delivered at each of the 16 FHCs for this 
study. The implementation of the pathway will take into 
account all patients in the non- communicable diseases 
register at the start of the cross- sectional study.
Setting
Target sites for implementation of DR screening and 
treatment in Thiruvananthapuram will include 16 FHCs 
for DR screening which represents the primary care 
centres where patients are screened for all complications 
of diabetes. The retinal images, captured by the trained, 
resident nursing staff will be sent to a newly developed 
reading centre at the Regional Institute of Ophthal-
mology, a tertiary care centre, where newly accredited 
graders will grade the images. Patients with screen- positive 
images will be referred to three secondary care hospitals 
(district hospitals). Severe cases that require complex 
interventions will be referred to the tertiary care centre, 
the tertiary for specialist management of DR.
Description of the standard of care
Currently, patients with diabetes are not systematically 
screened for DR in the public health system. Most patients 
present to the tertiary centre voluntarily either because 
of increased awareness of complications of diabetes or 
due to visual impairment. Therefore, the current stan-
dard of care will be captured as the number of patients 
presenting to the tertiary centre for an eye consultation 
for DR over a period of time as there is no baseline data 
in the primary and secondary care. This cross- sectional 
survey of the patients presenting at the FHCs will provide 
information on the uptake of screening of people regis-
tered in the non- communicable diseases register at the 
start of the study. The prevalence of DR and STDR of the 
screened population will be estimated from the numbers 
screened in all the non- communicable diseases registers 
during this period.
Evidence-based clinical intervention
The new DR care pathway is the intervention and is shown 
in figure 1. The pathway will span primary, secondary and 
tertiary care. The components of the pathway are:
1. DR screening of patients with diabetes registered in the 
non- communicable diseases register at FHCs (primary 
care). The retinal images will be graded remotely at 
the reading centre at the tertiary centre.
2. Prompt referral for timely treatment of STDR to sec-
ondary care and tertiary centres depending on the se-
verity of the DR.
3. Treatment of patients with sight threatening DR (at 
secondary and tertiary care).
Implementation strategies
The implementation strategies of the new DR care 
pathway are categorised as shown in table 1 into plan, 
finance, education, infrastructure, quality improvement 
and policy contexts. These categories are developed 
based on the discrete Expert Recommendations for 
Implementing Change (ERIC) taxonomy.20 21 The logic 
model is shown in figure 2.
Outcomes
Prespecified outcomes of the effectiveness of the DR 
pathway and the evaluation of the implementation 
strategy are tabulated in tables 2 and 3, respectively.
Data collection
Quantitative data
Effectiveness outcomes will originate from the data 
sources shown in table 2. Data collected by nurses or data 
operators from the EHR include age, gender, duration 
of diabetes, use of insulin, parental history of diabetes, 
other complications of diabetes including diabetic kidney 
disease, cardiovascular complications, and diabetic foot, 
random blood sugar results, urine dipstick test for albu-
minuria and blood pressure record. Other study- specific 
data collected by nurses or data operators on the day 
of screening include education status, occupation and 
income categories, and previous history of DR, cataract 
surgery or any other ocular history. In addition, they 
will measure body mass index, waist circumference and 
complete a lifestyle questionnaire on smoking, diet, phys-
ical activity, EQ- 5D vision bolt- on.24 The EQ- 5D vision 
bolt- on will be used to calculate the quality adjusted 
life- years and utility value for economic analysis. EQ- 5D 
alone does not capture visual acuity deficits.25 The EQ- 5D 
vision bolt- on asks patients to rate their health across six 
dimensions: mobility, self- care, usual activities, pain/
discomfort, anxiety/depression and vision. Each dimen-
sion is scored in five levels: no problems, slight prob-
lems, moderate problems, severe problems and extreme 
problems. A recent study provided utility values based on 
EQ- 5D vision bolt- on. The mapping was done in a clin-
ical trial cohort with macular oedema in central retinal 
vein occlusion.26
In the reading centre, the data collection will include 
the grade of retinopathy in both eyes, presence of cata-
ract and gradability of the retinal images. Data collected 
on referred patients will include numbers with ungrad-
able images due to cataract, treatment options offered for 
DR and review appointment.
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Qualitative data collection and analysis
Data sources used for evaluation of the implementation 
strategy are shown in table 3. These will include data from a 
structured interview of a maximum variable sample that will 
reflect the context (primary, secondary and tertiary care), 
and the functions and skill levels of the staff (eg, nurses, 
doctors, etc.). Based on pragmatic considerations, at least five 
nurses and five primary care doctors from 16 FHCs, three to 
five ophthalmologists from secondary and tertiary care, two 
data entry operators and five ASHAs and one health service 
administrator should be included to get the maximum vari-
ability. Verbal consent will be obtained from these health 
professionals. The interviews will be conducted by an inde-
pendent member from the GCRF/UKRI- funded team, who 
is not involved in this study, in the local language within the 
premises of the healthcare provider. The focus group will 
consist of groups of patients and staff within one FHCs. In 
addition, to the voice- recording of the interviews and focus 
group, interviewers will write field notes to describe the inter-
view situation. The interviews and focus group content will 
provide the basis for the data analysis, which will be based 
on a descriptive phenomenological approach without data 
or opinion interpretation and will include transcription, 
condensation, coding and categorisation using qualitative 
analysis tools. We will use the field notes collected during the 
interviews to inform the understanding of the phenomenon 
studied.
A survey of all referred patients will be done using a 
structured questionnaire to evaluate their satisfaction 
and their perception of the barriers and facilitators. All 
qualitative data will be coded using NVivo and analysed 
using descriptive phenomenological approach following 
the strategy.27 We will transcribe the interview data, iden-
tify statements or phrases, create formulated meanings 
or meaning units, aggregate formulated meanings and 
incorporate the result into descriptions.
Data monitoring
Data will be coded before entry into the study database by 
the clinical teams. Only anonymised extracted data from 
EHR by the nurses or data entry operators will be used for 
analysis. Data quality will be monitored by the study project 
manager. Anonymised data will be checked for range checks 
and data quality at University of East London by the study 
statistics team. The ORNATE India International Advisory 
Board will have an overview of the conduct of the project 
and the Executive Group consisting of the UK- India collabo-
rators will monitor the conduct of the study.
Figure 1 Proposed diabetic retinopathy care pathway. NPDR, non- proliferative diabetic retinopathy; PDR, proliferative diabetic 
retinopathy; PRP, pan- retinal photocoagulation; VEGF, Vascular Endothelial Growth Factor; VR, vitreo- retinal surgery.
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Table 1 Implementation strategies




Plan Conduct local needs 
assessment
The study team will conduct a situational analysis of data from self- referred patients.
Assess for readiness 
and identify barriers and 
facilitators
Assess barriers that may impede implementation of the DR care pathway, and strengths that can be 
used in the implementation effort by interviewing key stakeholders that is, family health centres staff, 
ophthalmologists in secondary and tertiary care, health service employees and patients.
Develop a formal 
implementation blueprint
The blueprint will be used to guide the implementation of the whole DR care pathway and will be 
updated with time.
Tailor strategies Regular collaborative meetings will be held to tailor the implementation strategies to address barriers 
and leverage facilitators that are identified during various steps in the implementation.
Stage implementation scale 
up and integration
The implementation will be staggered with five family health centres starting as pilots to enable small 
changes before gradually moving to other 11 centres. Addition of more centres during the staggered 
phase will be considered as sign of acceptability and feasibility.
Ensure integration of the DR care pathway into EHR. In the long term, the adoption of the DR care 
pathway across the state of Kerala will be considered as success.
Build a coalition Cultivate relationships with staff at family health centres and secondary care centres, data entry 
operators, EHR team, project manager and the Government of Kerala health service departmental 
staff in the implementation effort and create a learning system to incorporate practitioner feedback.
Develop academic 
partnerships
Partner with UK academic institutions for the purposes of shared training and bringing research skills 
to the implementation of the pathway.
Recruit, designate and train 
for leadership
A project manager will be recruited to manage the programme under the supervision of the non- 
communicable diseases lead. The Health Secretary will conduct periodic meetings with the project 
team to assess performance.
Obtain formal commitments A collaborative agreement is in place between Government of Kerala and Moorfields Eye Hospital, 
London, UK outlining their roles and responsibilities in the implementation of the DR care pathway.
Prepare patients to be 
active participants
Community level health workers will prepare patients to be active in their care, to ask questions and 
specifically to inquire about care guidelines, the evidence behind clinical decisions or about available 
evidence- supported treatments. Each patient will provide written consent to be screened for DR in 
this project as well as participate in interviews after verbal consent.
Inform local opinion leaders The Health Minister of the Kerala state and members of the local government will be briefed on the 
project and encouraged to be champions of the project to enable scale up to all family health centres 
in the state.
Finance Access new funding Use GCRF/UKRI funding to purchase smartphone retinal cameras and retinal lasers, develop EHR, 
train staff at family health centres and secondary care, employ project manager, data entry operators 
and personnel to conduct interviews, create study database linked to hand- held applications for data 
entry operators. State and local government funds will be sourced for scale up.
Incentivisation ASHAs will be incentivised to accompany participants with diabetes who are referred to secondary 
care for treatment.
Education Develop educational 
materials
Develop DR training modules and retinal image capture modules for family health centres staff
Develop laser training material to train ophthalmologists.
Distribute educational 
materials
Distribute educational materials (including guidelines, manuals and toolkits) in person, by mail and/
or electronically. Multiple training sessions are planned at each family health centres. The camera 
manufacturers will be invited to provide hands- on training on capturing good quality retinal images. 
Training on laser surgery will also be provided to the ophthalmologists at secondary care.
Conduct educational 
meetings
Hold meetings targeting different stakeholder groups (ophthalmologists, family health centres staff, 
ASHAs, patients). Three educational meetings are planned by the UK team to meet with the providers 
in the family health centres settings to share knowledge and educate providers about the DR care 
pathway and its integration into their clinical practice.
Achieve accreditation for 
graders of retinal images
Train and certify the optometrists in the Reading Centre in the tertiary centre to obtain accreditation 
as graders using the online international Test and Training for retinal graders.
Conduct ongoing training Nurses and doctors in the family health centres will receive on- going training on DR, pupil dilatation 
and capture of retinal images using low- cost smartphone retinal cameras.29 30
Create a learning 
collaborative
The Health Secretary of State will foster a collaborative learning environment to improve 
implementation of the DR care pathway.
Use train- the- trainer 
strategies
The UK team will first train a batch of family health centres nurses to capture retinal images and then 
some will be trained to train the rest of the nurses. The same cascading pathway will apply to laser 
training.
Work with educational 
institutions
Moorfields Eye Hospital staff will provide the necessary guidance and share knowledge on UK 
diabetic retinopathy screening pathway.
Make training dynamic All staff involved will receive continual online or face- to- face training.




The UK team from Moorfields Eye Hospital will provide ongoing consultation to support 
implementation of DR care pathway.
Continued
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Sample size
We have chosen the proportion of patients in the non- 
communicable diseases register with diabetes screened 
for DR as our primary outcome variable.
Justification of the choice of primary outcome: this 
variable captures the effectiveness of our intervention 
as well as the fidelity of implementation. Other facts 
that informed our choice of the primary outcome is that 
we expect a short implementation time of 7–9 months 
during which other outcomes such as number of patients 
treated may not be a feasible option. Therefore, we have 
estimated the sample size based on this primary outcome.




Infrastructure Centralise technical 
assistance
The project manager and the EHR team will provide central assistance focused on implementation 
issues. The telemedicine project will link the patient’s retinal images to EHR and transfer through a 
secure cloud to the tertiary centre, where the images will be graded for their DR status in a newly 
developed reading centre, with the results fed back to the family health centres.31
Change physical structure 
and equipment
Evaluate current configuration of family health centres consulting rooms to allow suitable furniture for 
cameras and adapt illumination to capture retinal photographs.
Change record systems Change record systems to allow better assessment of implementation or clinical outcomes by having 
data entry operators interview patients and input full data into EHR within the busy family health 
centres clinics.
Change service sites Change the timetable for clinics in secondary care to allow a patients referred from primary care to 
access treatment.
Revise professional roles The non- communicable diseases lead will be delegated to take on the responsibility of implementing 
this DR care pathway in Thiruvananthapuram aiming for a Kerala state- wide roll out.
Quality improvement Develop and implement 
tools for quality monitoring
Develop, test and introduce into quality- monitoring systems the right input—the appropriate 
language for the consent form, protocols on DR screening, grading retinal images and measures of 
processes, patient outcomes and implementation outcomes.
Develop and organise 
quality monitoring systems
Develop and organise systems and procedures that monitor clinical processes and/or outcomes for 
the purpose of quality assurance and improvement.
Audit and provide feedback Collect and summarise clinical performance data every month and feedback to family health centres 
and secondary care staff to monitor, evaluate and modify pathway for acceptability to patients and 
staff. A continuous monitoring of retinal image quality and gradability, and the referral pathway will be 
done to cyclically input change into the DR pathway to improve the quality and integration.
Conduct cyclical small 
tests of change
Staggered set up of family health centres to allow implementation of changes in a cyclical fashion 
using small tests of change before taking changes system- wide. Tests of change benefit will be 
measured continually by increase uptake of training, screening, referral and treatment.
Use data experts The EHR team will develop an application for the data entry operators to collect data. The UK 
collaborators will collaborate in the analysis of the data.
Use data warehousing 
techniques
Integrate clinical records from this research project into EHR on an on- going basis.
Capture and share local 
knowledge
Capture local knowledge from implementation sites on how staff and doctors make something work 
in their family health centres and then share it with other centres.
Obtain and use patients 
feedback
The participating patients will be asked to provide feedback on the implementation effort.
Promote adaptability Identify ways the DR care pathway can be tailored to meet local needs and clarify which elements of 
the pathway must be maintained to preserve fidelity.
Provide clinical supervision The Director of the tertiary centre will provide the overall clinical supervision of the whole DR care 
pathway. He will also delegate ophthalmologists to provide ongoing supervision for the optometrists 
involved in grading retinal images.
Provide local technical 
assistance
Develop and use a system to deliver technical assistance focused on implementation issues using 
relevant service providers.
Purposely re- examine the 
implementation
Monthly monitoring of screened patients at each family health centre, barriers observed and small 
changes that are required will be implemented to continuously improve the pathway.
Remind clinicians Primary care doctors in family health centres will receive monthly newsletter on the numbers 
recruited across all centres to highlighting successes and providing potential solutions to issues 
encountered.
Policy contexts Issue Government of 
Kerala approval to enable 
dilatation of pupils of 
patients under supervision 
of family health centres 
doctors
Ensure doctors at family health centres receive approval for mydriasis in order to deliver the DR care 
pathway.
Mandate change The Health Secretary of State will provide leadership to ensure the prioritisation of the 
implementation of the DR care pathway.
ASHAs, accredited social health activists; DR, diabetic retinopathy; EHR, electronic health records; GCRF/UKRI, Global Challenge Research Fund/UK Research and Innovation.
Table 1 Continued
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Our calculations are complicated by the expected 
increase in number of people with diabetes in the non- 
communicable diseases register as public awareness of 
diabetes and DR increases so the denominator of numbers 
screened will be the number of people registered in the 
non- communicable diseases in each FHCs at the start of 
the cross- sectional study. There is no data on the base-
line proportion of patients that attend the tertiary centre 
for screening. The prevalence of diabetes is between 10% 
and 16% in Thiruvananthapuram of which 8% are esti-
mated to have DR and 3% to have STDR but about 20% 
may have to be referred. Assuming a finite population of 
40 000 patients with diabetes, a simple random sample 
of 377 patients will be needed. However, we expect large 
design effects due to clustering patients within FHCs. 
There is not enough data to calculate the value of this 
design effect and therefore we assume it to be 3 to give a 
final sample size of 1131, which is equivalent to assuming 
a within- FHCs intracluster correlation coefficient of 
approximately 0.03 (n=16 FHCs) with negligible residual 
clustering by the intermediate cluster level of ASHAs, 
where mean cluster size is smaller.
As described by Becker et al in mammography 
screening,28 we expect sources of bias in the implemen-
tation programme that will likely influence the sample 
size calculation. Unscreened DR cases that already exist 
in the community may contribute to an over- estimation of 
the effect of screening. We expect lead- time bias because 
of our short implementation period and so some DR in 
the community may be missed. A comparison of numbers 
with DR in FHCs with longer implementation period with 
those of shorter period may adjust for this bias. We intend 
to provide a descriptive analysis as well as a temporal 
comparison using time series analysis.
Statistical analyses
We will create a complete case data set of the cross- 
sectional survey for use in the analyses of effectiveness and 
assess the potential impact of missing data using sensitivity 
analysis incorporating a range of optimistic and pessi-
mistic scenarios for the impact of missing data. We will 
model two outcomes that we hypothesised would be influ-
enced by the intervention: (1) uptake of DR screening 
(primary outcome) and (2) numbers of patients referred 
for STDR as a result of screening. We will use bivariate 
logistic regression models to assess crude associations 
between sociodemographic factors such as age, gender, 
education, income and living arrangements, and other 
clinical data with DR and STDR and use fractional poly-
nomials to account for the form of continuous covariates 
to predict uptake of DR screening. Factors associated with 
a p<0.25 will be candidates for inclusion in the multivari-
able logistic regression models. We will test interactions 
among identified main effects to capture improvement in 
model prediction assessed by reduced residual variance- 
based statistics. To account for the staggered entry into 
the study, we will add a variable indicating the month 
of entry of each FHCs into the programme (eg, 1. if the 
FHC join in the first month of the programme, 2. if in 
the second month and so on). A non- significant coeffi-
cient for this variable will suggest the staggered approach 
had no effect and a significant coefficient will allow the 
effect to be quantified for each FHC. In our final adjusted 
model, we will consider associations with a p<0.05 as 
statistically significant. Adequacy of model discrimination 
and calibration will be assessed using receiver operating 
characteristic curves. The validation of the telemedi-
cine will be reported as the agreement (kappa statistics) 
between screen positive patients graded by the graders 
Figure 2 The implementation research logic model. DR, diabetic retinopathy; FHC, family health centres.
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at the reading centre versus the DR grade as recorded by 
the ophthalmologists in secondary care centres. A kappa 
coefficient of 0.6 or higher was prespecified to indicate 
validity.
Patient and public involvement
A patient and public group will be involved in plans to 
disseminate the study results and provide their input on 
the scale- up of this DR care pathway, should the imple-
mentation in Thiruvananthapuram be deemed successful 
by the Government of Kerala.
ETHICS AND DISSEMINATION
The study was approved by Indian Medical Research 
Council (2018-0551). The study complies with the 
guidelines of the Declaration of Helsinki. Results of this 
research are expected to be disseminated through stake-
holder reports and via scientific forums, specifically peer- 
reviewed publications and conference presentations. All 
participants will give written informed consent prior to 
entry to the study by the FHCs nurses and will be made 
aware that participation is strictly voluntary.
DISCUSSION
At the conclusion of this study, we hope to assess the effec-
tiveness and implementation outcomes of a complex DR 
care pathway integrating care at primary, secondary and 
tertiary care, covering a proportion of the diabetic popu-
lation in Thiruvananthapuram. The study will set the 
scene for a policy for State- wide Screening and Treatment 
Pathway for Diabetes. Early identification of STDR and 
other complications due to this holistic approach and 
timely treatment are expected to have a positive impact 
on rates of blindness, chronic kidney disease, cardio-
vascular complications and thereby improve health, 
reduce multimorbidity and mortality. A DR pathway that 
straddles primary, secondary and tertiary levels of care, 
leveraging technology may have advantages of cost effec-
tiveness and ease of implementation in LMICs compared 
with the current practice of detection and management 
of self- reported cases in tertiary centres.
This study outlines how the effectiveness of a DR care 
pathway and its implementation will be evaluated.21 22 This 
study is timely given the increasing numbers of people 
with diabetes and pressure on finances available for 
Table 2 DR pathway (intervention)- related outcomes
Outcomes Indicators Source of data
Clinical effectiveness  ► Proportion of people screened for DR in each family health centres 
over 12 months.
 ► Proportion of referred patients with STDR.
 ► Proportion of ungradable retinal images and percentage of cataract 
identified from referring these patients.
 ► Risk and complication burden in people screened for DR
 ► Presenting visual acuity of those referred from the DR pathway 
compared with those who self- referred to secondary care.
 ► Generalisability of the prevalence data compared with house- to- 
house survey in a neighbouring district.
Data from monthly entries into EHR and study database.
−
Safety Data on complications of the DR pathway EHR and study database
Cost- effectiveness The key outcome is the number of cases of severe visual impairment 
or blindness due to STDR averted as a result of the new DR care 
pathway and resultant QALY gain.
Estimated QALY gain from laser treatment of STDR and from cataract 
surgery, using utility values from Rachapelle et al.32
Assumption that the effect of no screening is as in historic studies that 
reported the rate at which STDR leads to blindness if left untreated.
Data collected in the study, data from the literature and 
expert opinion where data could not be collected.
Efficiency Efficiency is defined as optimal use of the service. For this purpose, 
we will first estimate the time required to process one patient from the 
path- process analysis. This estimate will be used to determine the 
number of patients who can be seen on a day. We will then calculate 
(1−number of patients screened)/number of patients who can be 
screened). Proportion can be used in a p- type control chart.33
Capture efficiencies in structures, resources and 
processes across the DR care pathway from staff 
interviews.
Path- process mining of patients screened in family health 
centres analysis will be based on detailed time- event logs 
of approximately 70 patients from the 16 FHCs
Patient satisfaction Patients willingness to be screened and their satisfaction with the 
information provided to them and the care they received
Patient interviews and telephone survey of patients 
referred to secondary care for treatment
Timeliness Path- process mapping at family health centres to understand delays 
in pathway
Reasons for non- attendance for those referred to secondary care for 
treatment of STDR
Path- process mapping at family health centres to 
understand delays in DR care pathway
Patient survey and secondary care records
Equity Age and gender- based prevalence of DR and STDR will be reported 
on consented patients from all family health centres. Reasons of non- 
referral of patients that require referrals will be recorded. Numbers 
denied screening despite willingness to be screened will also be 
reported.
Data from EHR and study database.
DR, diabetic retinopathy; EHR, electronic health records; FHCs, family health centres; QALY, quality- adjusted life year; STDR, sight- threatening diabetic retinopathy.
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Table 3 Outcomes of the evaluation of the implementation strategy
Outcomes Indicators Assessment and data source
Acceptability Willingness of each family health centres to be 
involved in the DR care pathway.
Staff willingness to train
patients acceptability of the pathway.
Assessment: Readiness to implement the DR care pathway in the 16 family health 
centres and any reasons for delay.
Data source: Clinical performance from family health centres that will include monthly 
uptake of DR screening at each centre and any reports on barriers causing delays in 
implementation provided by the project manager.
Assessment: Proportions of trained ASHAs, nurses and doctors per family health 
centres, increase in doctors trained in laser surgery in secondary care, proportions 
willing to be included in train the trainer programme. The denominator will be total 
numbers of each personnel available to be trained on the date of implementation.
Data sources: Accreditation and certification records; structured interviews of at least 5 
nurses and 5 primary care doctors from 16 family health centres, 3–5 ophthalmologists 
from secondary and tertiary care, 2 data entry operators and 5 ASHAs and 1 health 
service administrator to understand challenges for acceptance.
Assessment: Screening attendances per family health centres over 12 months.
Data sources: Clinical performance data and a telephone questionnaire survey 
for screened and referred patients to evaluate reasons for attendance and non- 
attendance.
Adoption Uptake of DR care pathway at primary, secondary 
and tertiary care.
Uptake of training by staff.
Uptake of screening programme by patients.
Adoption of DR care pathway by the Government of 
Kerala for state- wide implementation.
Assessment: Proportion of staff at primary, secondary and tertiary care willing to 
integrate DR care pathway in their workload.
Data source: Family health centres data and staff interviews.
Assessment: Demand training sessions; attendance rates at training sessions.
Data source: Number of training sessions and attendance registers at training 
sessions.
Assessment: Increase in proportions of patient screened over 12 months.
Data source: EHR and study database.
Assessment: A policy paper by the Government of Kerala for state- wide adoption of 
the DR care pathway as part of diabetes care for all patients.
Data source: A detailed scale- up plan will be developed for each district based on the 
clinical and cost- effectiveness data from this study to inform policy.
Appropriateness Appropriateness of family health centres for DR 
screening.
Appropriateness of the complex DR care pathway 
across primary and secondary care.
Appropriateness of referrals to secondary care.
Assessment: Qualitative data on barriers and facilitators of the delivery of screening 
and treatment in secondary care.
Data sources: Interview of staff at family health centres and secondary care, patient 
telephone survey on pathway from FHCs to secondary care.
Assessment: False positive referrals from data collection at secondary care.
Data sources: Study database; data from patient telephone survey.
Cost Costs to the Government of Kerala and societal 
costs of the DR screening programme and 
subsequent treatment.
Assessment: Costs of the DR screening and treatment costs in total and per person, 
including the costs of staff training and cameras (suitably annuitised), staff costs and 
travel costs of patients.
Data sources: Data collected in the study baseline and data from other services in 
India and from the literature.
Feasibility Screening rate per family health centres.
Barriers to monthly screening uptake.
Assessment: Monthly increase in numbers of FHCs added to the programme.
Data source:Interview and monthly report from project manager on facilitators and 
barriers on each part of the pathway.
Fidelity Degree of the DR care pathway implementation.
Validation of the DR grading within the telemedicine 
pathway.
Delivery of training and the impact on the DR care 
pathway.
Assessment: Fidelity evaluation in 16 family health centres using a path- process 
analysis of the screening to identify the common screening pathway across centres.
Data source: The path- process analysis will be based on detailed time- event logs of 70 
patients from the 16 family health centres; a telephone follow- up of referred patients to 
evaluate uptake of referrals.
Assessment: Validation of the DR grading will be assessed by the agreement of the 
DR grade reported by the optometrists at the reading centre in the tertiary centre and 
those reported by the ophthalmologists in the secondary care centres.
Data sources: DR grading of referred patients obtained from the reading centre vs 
secondary care.
Assessment: Increase in numbers of trained staff per month.
Data sources: Staff interviews, structured observations and review of facility records. 
The proportions of doctors trained on laser delivery; data quality on the database; 
increase in non- communicable diseases registration following start of programme 
due to training of ASHA workers on diabetes and DR; increase in numbers of patients 
treated for STDR following training.
Penetration Increase patient awareness of diabetes and DR and 
uptake of the DR screening pathway in patients with 
diabetes.
Assessment: Increase uptake of DR screening by patients registered in non- 
communicable diseases registers.
Data sources: from non- communicable diseases register and EHR.
Sustainability Policy makers to prepare policy on up- scale and 
sustainability plan for DR pathway.
Integration of DR pathway in weekly activities in 
FHCs
Assessment: Availability of a policy paper from Government of Kerala on state- wide 
scale up of the DR care pathway. This will be considered a success of the programme.
Data sources: Scale up plan for other districts including plan to purchase retinal 
cameras and acceptance of guidelines and training material for state- wide roll out.
Assessment: Integration of DR pathway in EHR.
Data source: EHR records of DR screening as part of non- communicable diseases 
care pathway.
ASHA, accredited social health activists; DR, diabetic retinopathy; EHR, electronic health records; FHCs, family health centres; STDR, sight- threatening diabetic retinopathy.
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healthcare, necessitating task shifting to enable better 
coverage of the population. The study will also examine 
the organisation functions such as structure, resources 
and processes that would contribute to better outcomes. 
We will also examine whether this additional task is 
feasible given the current skill levels and workload of 
FHCs and secondary hospitals. The study will reveal 
whether current health seeking behaviour of patients will 
support screening, especially when an invasive procedure 
is requested when there is no obvious impact on quality 
of life of the patient. By addressing a key gap in knowl-
edge due to lack of research in this area, we will be able 
to decipher the barriers and facilitators that influence 
the successful implementation of such a programme in 
the public system in India. The results of this study may 
inform the adoption of this pathway in other areas in 
India and globally. However, the complexity and number 
of implementation strategies, local contextual factors and 
lack of validated implementation outcomes may limit 
generalisability of the results and implementation of this 
pathway elsewhere.
There are limitations, however, to the study design. We 
do not have baseline data on DR screening in the study 
location as these screening programmes are non- existent. 
For this reason, we are examining the effectiveness of the 
pathway in terms of presenting visual acuity for referable 
cases as ‘proximal’ outcomes. In addition, when there is 
no concurrent control group, causal inferences are diffi-
cult to make and may lead to both measured and unmea-
sured biases. When examining implementation, logistical 
issues, variations in healthcare facilities, socioeconomic 
variation and quality of healthcare personnel may likely 
affect our study. However, the study design avoids the 
ethical challenges of having a control group with no DR 
screening. Therefore, the study design is by necessity 
non- randomised and observational and will rely on newly 
trained staff members to collect data, which is likely to 
differ in completeness between the 16 FHCs. We expect 
an increase in referral rates after implementation of the 
intervention due to better public awareness, increasing 
knowledge of ASHAs and improved case ascertainment, 
at least in some FHCs . We will also examine the impact 
of cataract in the community and this has not been 
studied before in any other DR pathway. We have tried 
to minimise the limitations by the use of robust statistical 
techniques and the use of various data sources to elicit a 
greater understanding of how the programme will lead to 
better health outcomes.
One of the strengths of this study is that quantita-
tive data backed by qualitative data will be collected 
to strengthen our findings and enable generalisation 
of our findings. Second, we will use robust statistical 
methods to reduce bias including selection bias and 
other confounders. Finally, the access to and collabora-
tion with the UK is a key strength of the study, as it facil-
itates the codevelopment of the interventions from the 
outset. Active involvement of policy makers engaged in 
transformation of primary care to screen for and address 
complications of non- communicable diseases who value 
research to generate evidence for policy making and 
who are prepared to learn from, and adapt the DR 
care pathway based on implementation experience is 
a unique feature of this study. Findings on the mecha-
nisms and contexts that optimise the implementation of 
this complex multifaceted intervention using the ERIC 
taxonomy will be useful to those developing and imple-
menting these programmes in other health systems. The 
health economic model may highlight the health expen-
diture required at individual, family and Kerala State level 
for forecasting and planning health budgets.
Perhaps the most important aspect of the chosen eval-
uation is that it is built within a simultaneous developing 
public health strategy on population- based screening 
of diabetes and hypertension and a recently introduced 
EHR called eHealth. Conducting research in such an 
environment is a good example of health policy and 
systems research.
Despite the limitations, this study holds promise for 
providing high- quality data and detailed implementation 
information on a complex intervention in a resources- 
limited setting. We hope to contribute to the literature 
on the implementation and effectiveness of DR screening 
and treatment in the public health sector in LMICs.
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